17.10.2016 • NewsDede WillamsPfizerAllergan

Pfizer Loses Patent Appeal Against Allergan

(c) ER_09/Shutterstock
(c) ER_09/Shutterstock

Pifzer has lost its appeal of a UK patent dispute with Allergan over Lyrica, one of the US pharmaceutical giant blockbuster drugs, with annual global sales of around $5 billion. It now hopes to take the appeal to the UK Supreme Court.

In its verdict last week, the London court upheld last year’s High Court ruling that the generic pregabalin, produced by Allergan‘s Actavis unit – at the time an independent company and recently acquired by Israel’s Teva Pharmaceutical Industries – did not infringe Pfizer patents. That court at the same time overturned Pfizer’s patent UK patent for use of Lyrica as a pain relief drug.

The High Court also charged Pfizer with threatened doctors and pharmacists for prescribing the generic. The company denied using threats but acknowledged at the time mistakes in communicating with the UK medical sector. Lyrica was initially developed by Pfizer as a treatment for epilepsy. Following the expiration of the patent for this indication in 2014, Actavis launched its low-priced version as a painkiller. Pfizer has also sued Dr. Reddy’s Laboratories of  India as well as Teva over their generic pregabalin products.

Lawyers for Actavis said the case has international implications as other European courts in Europe are having to deal with drug patents for secondary uses. The London decision “gives guidance,” they said. Pfizer’s UK sales of Lyrica total just under £250m, with most sales in the pain relief indication.  Lyrica is not only Pfizer’s best-selling drug but is seen to be as the world’s best-selling medication for treating diseases of the central nervous system.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.